MedTrace Logo

CASAD for Severe Diarrhea in the Emergency Department

NCT02018653 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2018-07-26

Study results available
· View outcomes & findings →

Summary

The goal of this clinical research study is to learn if calcium alumina-silicate (CASAD) can help to stop your diarrhea. Researchers also want to know if this drug can help decrease the duration of your diarrhea.

In this study, CASAD will be compared to a placebo. A placebo is not a drug. It looks like the study drug but it is not designed to treat any disease or illness. It is designed in this study to be compared with the study drug to learn if the study drug has any real effect.

Conditions

Interventions

DRUG

Calcium Alumina-Silicate (CASAD)

1 gram by mouth every 6 hours for up to 6 days.

OTHER

Placebo

1 by mouth every 6 hours for up to 6 days.

BEHAVIORAL

Questionnaire

Questionnaire completion at baseline about diarrhea and other symptoms.

Sponsors & Collaborators

  • Salient Pharmaceuticals Incorporated

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Sai-Ching J. Yeung, MD,PHD · M.D. Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02018653 on ClinicalTrials.gov